테노포비르 디소프록실 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.6%로 47억 2,000만 달러로 성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 장기간 작용하는 테노포비르 제제에 대한 수요가 증가하고, 신규 항바이러스제와의 병용 요법에 대한 주목 증가, 신규 테노포비르 병용 요법에 대한 규제 당국의 승인 증가, 소아용 제제에의 중점화, 노출 후 예방에 있어서의 테노호비르의 사용 증가 등에 의한 것으로 예측됩니다. 주요 동향으로는 신규 약물전달 시스템의 개발, 의약품 개발에 있어서의 인공지능의 통합, 병용 요법의 진전, 나노 테크놀로지를 이용한 딜리버리의 혁신, 합제 요법의 진전 등을 들 수 있습니다.
HIV와 에이즈의 유병률 증가는 테노포비르 디소프록실 시장의 성장을 이끌 것으로 예측됩니다. HIV와 AIDS는 CD4 세포를 공격하여 면역계를 약화시키고 몸을 감염과 질병에 걸리기 쉽게 만드는 만성 바이러스 감염입니다. 이러한 질병의 유병률 증가는 무방비 성적 접촉, 인식 부족, 건강 관리 접근 제한, 약물 내성 바이러스 균주의 출현 등의 요인 때문입니다. HIV/AIDS 환자가 증가함에 따라 치료 및 예방에 사용되는 주요 항-레트로바이러스 약물인 테노포비르 디소프록실 수요가 증가하고 있습니다. 예를 들어, 2024년 7월 스위스에 본부를 둔 정부기관인 유엔합동 에이즈 계획(UNAIDS)은 2022년 말까지 세계에서 약 3,950만명이 HIV에 감염되었고 같은 해 약 130만명의 신규 감염이 기록되었다고 보고했습니다. 게다가 2022년에는 에이즈 관련 질환에 의한 사망자가 세계에서 약 63만명 발생하고, 2023년에는 HIV와 함께 사는 사람의 수는 3,990만명(3,610만명-4,460만명)으로 증가했습니다. 그 결과 HIV와 에이즈의 유병률 증가는 테노포비르디소프록실 시장의 성장을 가속하고 있습니다.
또한 B형 간염의 유병률 증가도 테노포비르디소프록실 시장의 확대에 기여할 것으로 예측됩니다. B형 간염은 간을 표적으로 하는 바이러스 감염으로, 감염된 혈액이나 체액과의 접촉을 통해 전염되는 급성 및 만성 질환을 유발할 수 있습니다. 주산기 감염, 안전하지 않은 의료 행위, 백신 접종률의 부족, 감염 집단에 있어서의 만성 감염의 지속이라고 하는 요인이, B형 간염 환자 증가를 촉진하고 있습니다.테노포비르 디소프록실은 만성 B형 간염에 널리 사용되는 치료법으로, 바이러스 복제를 억제하고 간장애를 최소화하는 데 도움이 되고 있습니다. 240만명이 B형 간염에 감염되어 있다고 추정하고 있으며, 약 3분의 2는 자신의 증상을 깨닫지 못할 가능성이 있다고 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 테노포비르 디소프록실 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계 테노포비르 디소프록실 시장 : 성장률 분석
- 세계 테노포비르 디소프록실 시장 실적 : 규모와 성장, 2019-2024
- 세계 테노포비르 디소프록실 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 테노포비르 디소프록실 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 테노포비르 디소프록실 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 정제
- 분말
- 세계의 테노포비르 디소프록실 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 온라인 약국
- 소매 약국
- 도매업체 또는 판매자
- 세계의 테노포비르 디소프록실 시장 : 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 클리닉
- 세계의 테노포비르 디소프록실 시장 : 태블릿유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 단제정
- 고정용량 배합정
- 세계의 테노포비르 디소프록실 시장 : 분말유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 경구 분말
- 재구성 가능한 분말
제7장 지역별/국가별 분석
- 세계의 테노포비르 디소프록실 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 테노포비르 디소프록실 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 테노포비르 디소프록실 시장 : 경쟁 구도
- 테노포비르 디소프록실 시장 : 기업 프로파일
- Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
- Teva Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
- Cipla Ltd Overview, Products and Services, Strategy and Financial Analysis
- Lupin Limited Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
- Mylan NV
- Blanver
- SMS Pharmaceuticals
- Bajaj Healthcare
- Mangalam Drugs & Organics Ltd
- Nortec Quimica
- Arene Lifesciences
- Cdymax
- HRV Global Life Sciences
- Pipelinepharma
- Qilu Pharmaceutical
- Jai Radhe Sales
- Sinoway Industrial Co. Ltd
- Aurisco Pharmaceutical
- Huangshi Fuertai Pharmaceutical Tech Co. Ltd
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 테노포비르 디소프록실 시장 2029 : 새로운 기회를 제공하는 국가
- 테노포비르 디소프록실 시장 2029 : 새로운 기회를 제공하는 부문
- 테노포비르 디소프록실 시장 2029 : 성장 전략
제36장 부록
SHW
Tenofovir disoproxil is a medication used for treating HIV-1 infection and chronic hepatitis B. As a prodrug of tenofovir, it converts into its active form in the body, inhibiting viral replication. It belongs to the nucleotide reverse transcriptase inhibitors (NRTIs) class, which blocks a crucial enzyme required for viral multiplication.
The primary forms of tenofovir disoproxil are tablets and powder. Tablets are solid medicinal forms designed for easy swallowing, dissolving in the digestive system to release the active ingredient either gradually or immediately. The medication is distributed through online pharmacies, retail pharmacies, and wholesalers or distributors, with applications primarily in hospitals and clinics.
The tenofovir disoproxil market research report is one of a series of new reports from The Business Research Company that provides tenofovir disoproxil market statistics, including the tenofovir disoproxil industry's global market size, regional shares, competitors with a tenofovir disoproxil market share, detailed tenofovir disoproxil market segments, market trends and opportunities, and any further data you may need to thrive in the tenofovir disoproxil industry. This tenofovir disoproxil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The tenofovir disoproxil market size has grown strongly in recent years. It will grow from $3.58 billion in 2024 to $3.79 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be credited to increased awareness and early detection of viral infections, the rising prevalence of hepatitis B infections, the expansion of generic drug manufacturing for tenofovir disoproxil, a growing number of clinical trials supporting its efficacy, and increased healthcare funding for infectious disease treatment.
The tenofovir disoproxil market size is expected to see strong growth in the next few years. It will grow to $4.72 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth during the forecast period can be credited to the rising demand for long-acting tenofovir formulations, an increasing focus on combination therapies with newer antivirals, growing regulatory approvals for novel tenofovir combinations, a heightened emphasis on pediatric formulations, and the increasing use of tenofovir in post-exposure prophylaxis. Key trends include the development of novel drug delivery systems, the integration of artificial intelligence in drug development, advancements in combination therapies, innovations in nanotechnology-based delivery, and progress in fixed-dose combination therapies.
The increasing prevalence of HIV and AIDS is expected to drive the growth of the tenofovir disoproxil market. HIV and AIDS are chronic viral infections that weaken the immune system by attacking CD4 cells, making the body more susceptible to infections and diseases. The rising prevalence of these conditions is attributed to factors such as unprotected sexual contact, lack of awareness, limited access to healthcare, and the emergence of drug-resistant virus strains. The growing number of HIV and AIDS cases is increasing the demand for tenofovir disoproxil, a key antiretroviral drug used for treatment and prevention. For example, in July 2024, the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, reported that by the end of 2022, approximately 39.5 million people were living with HIV worldwide, with about 1.3 million new infections recorded that year. Additionally, in 2022, around 630,000 deaths from AIDS-related illnesses occurred globally, with the number of people living with HIV rising to 39.9 million (36.1 million-44.6 million) in 2023. As a result, the increasing prevalence of HIV and AIDS is fueling the growth of the tenofovir disoproxil market.
The growing prevalence of hepatitis B is also expected to contribute to the expansion of the tenofovir disoproxil market. Hepatitis B is a viral infection that targets the liver and can lead to both acute and chronic disease, transmitted through contact with infected blood or bodily fluids. Factors such as perinatal transmission, unsafe medical practices, lack of vaccination coverage, and the persistence of chronic infections in affected populations are driving the rise in hepatitis B cases. Tenofovir disoproxil is a widely used treatment for chronic hepatitis B, helping to suppress viral replication and minimize liver damage. For instance, in March 2023, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, estimated that between 580,000 and 2.4 million people in the United States are living with hepatitis B infection, with about two-thirds potentially unaware of their condition. Consequently, the increasing prevalence of hepatitis B is contributing to the demand for tenofovir disoproxil.
Leading companies in the tenofovir disoproxil market are focusing on innovative formulations, such as combination therapies, to enhance HIV/AIDS treatment and maintain a competitive edge. Combination therapy involves the simultaneous use of two or more treatments to improve therapeutic outcomes and patient well-being. For instance, in July 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus (HBV) infection in pediatric patients aged six years and older, weighing at least 25 kg, with compensated liver disease. The FDA's approval was based on data from a Phase II clinical trial demonstrating the drug's safety and efficacy in children as young as six years old.
Major players in the tenofovir disoproxil market are Gilead Sciences Inc., Viatris Inc., Teva Pharmaceuticals Limited, Cipla Ltd, Lupin Limited, Mylan NV, Blanver, SMS Pharmaceuticals, Bajaj Healthcare, Mangalam Drugs & Organics Ltd, Nortec Quimica, Arene Lifesciences, Cdymax, HRV Global Life Sciences, Pipelinepharma, Qilu Pharmaceutical, Jai Radhe Sales, Sinoway Industrial Co. Ltd, Aurisco Pharmaceutical, Huangshi Fuertai Pharmaceutical Tech Co. Ltd.
North America was the largest region in the tenofovir disoproxil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tenofovir disoproxil report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the tenofovir disoproxil market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tenofovir disoproxil market consists of sales of active pharmaceutical ingredients (APIs), branded formulations, generic formulations, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tenofovir Disoproxil Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on tenofovir disoproxil market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for tenofovir disoproxil ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tenofovir disoproxil market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Tablet; Powder
- 2) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Wholesalers Or Distributors
- 3) By Application: Hospital; Clinic
- Subsegments:
- 1) By Tablet: Single-Drug Tablets; Fixed-Dose Combination Tablets
- 2) By Powder: Oral Powder; Reconstitutable Powder
- Companies Mentioned: Gilead Sciences Inc.; Viatris Inc.; Teva Pharmaceuticals Limited; Cipla Ltd; Lupin Limited
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Tenofovir Disoproxil Market Characteristics
3. Tenofovir Disoproxil Market Trends And Strategies
4. Tenofovir Disoproxil Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Tenofovir Disoproxil Growth Analysis And Strategic Analysis Framework
- 5.1. Global Tenofovir Disoproxil PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Tenofovir Disoproxil Market Growth Rate Analysis
- 5.4. Global Tenofovir Disoproxil Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Tenofovir Disoproxil Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Tenofovir Disoproxil Total Addressable Market (TAM)
6. Tenofovir Disoproxil Market Segmentation
- 6.1. Global Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tablet
- Powder
- 6.2. Global Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Online Pharmacies
- Retail Pharmacies
- Wholesalers Or Distributors
- 6.3. Global Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital
- Clinic
- 6.4. Global Tenofovir Disoproxil Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Single-Drug Tablets
- Fixed-Dose Combination Tablets
- 6.5. Global Tenofovir Disoproxil Market, Sub-Segmentation Of Powder, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Powder
- Reconstitutable Powder
7. Tenofovir Disoproxil Market Regional And Country Analysis
- 7.1. Global Tenofovir Disoproxil Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Tenofovir Disoproxil Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Tenofovir Disoproxil Market
- 8.1. Asia-Pacific Tenofovir Disoproxil Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Tenofovir Disoproxil Market
- 9.1. China Tenofovir Disoproxil Market Overview
- 9.2. China Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Tenofovir Disoproxil Market
- 10.1. India Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Tenofovir Disoproxil Market
- 11.1. Japan Tenofovir Disoproxil Market Overview
- 11.2. Japan Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Tenofovir Disoproxil Market
- 12.1. Australia Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Tenofovir Disoproxil Market
- 13.1. Indonesia Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Tenofovir Disoproxil Market
- 14.1. South Korea Tenofovir Disoproxil Market Overview
- 14.2. South Korea Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Tenofovir Disoproxil Market
- 15.1. Western Europe Tenofovir Disoproxil Market Overview
- 15.2. Western Europe Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Tenofovir Disoproxil Market
- 16.1. UK Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Tenofovir Disoproxil Market
- 17.1. Germany Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Tenofovir Disoproxil Market
- 18.1. France Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Tenofovir Disoproxil Market
- 19.1. Italy Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Tenofovir Disoproxil Market
- 20.1. Spain Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Tenofovir Disoproxil Market
- 21.1. Eastern Europe Tenofovir Disoproxil Market Overview
- 21.2. Eastern Europe Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Tenofovir Disoproxil Market
- 22.1. Russia Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Tenofovir Disoproxil Market
- 23.1. North America Tenofovir Disoproxil Market Overview
- 23.2. North America Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Tenofovir Disoproxil Market
- 24.1. USA Tenofovir Disoproxil Market Overview
- 24.2. USA Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Tenofovir Disoproxil Market
- 25.1. Canada Tenofovir Disoproxil Market Overview
- 25.2. Canada Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Tenofovir Disoproxil Market
- 26.1. South America Tenofovir Disoproxil Market Overview
- 26.2. South America Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Tenofovir Disoproxil Market
- 27.1. Brazil Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Tenofovir Disoproxil Market
- 28.1. Middle East Tenofovir Disoproxil Market Overview
- 28.2. Middle East Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Tenofovir Disoproxil Market
- 29.1. Africa Tenofovir Disoproxil Market Overview
- 29.2. Africa Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Tenofovir Disoproxil Market Competitive Landscape And Company Profiles
- 30.1. Tenofovir Disoproxil Market Competitive Landscape
- 30.2. Tenofovir Disoproxil Market Company Profiles
- 30.2.1. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Teva Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Cipla Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Lupin Limited Overview, Products and Services, Strategy and Financial Analysis
31. Tenofovir Disoproxil Market Other Major And Innovative Companies
- 31.1. Mylan NV
- 31.2. Blanver
- 31.3. SMS Pharmaceuticals
- 31.4. Bajaj Healthcare
- 31.5. Mangalam Drugs & Organics Ltd
- 31.6. Nortec Quimica
- 31.7. Arene Lifesciences
- 31.8. Cdymax
- 31.9. HRV Global Life Sciences
- 31.10. Pipelinepharma
- 31.11. Qilu Pharmaceutical
- 31.12. Jai Radhe Sales
- 31.13. Sinoway Industrial Co. Ltd
- 31.14. Aurisco Pharmaceutical
- 31.15. Huangshi Fuertai Pharmaceutical Tech Co. Ltd
32. Global Tenofovir Disoproxil Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Tenofovir Disoproxil Market
34. Recent Developments In The Tenofovir Disoproxil Market
35. Tenofovir Disoproxil Market High Potential Countries, Segments and Strategies
- 35.1 Tenofovir Disoproxil Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Tenofovir Disoproxil Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Tenofovir Disoproxil Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
